Correlation Between Enzymatica Publ and Moberg Pharma

Can any of the company-specific risk be diversified away by investing in both Enzymatica Publ and Moberg Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enzymatica Publ and Moberg Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Enzymatica publ AB and Moberg Pharma AB, you can compare the effects of market volatilities on Enzymatica Publ and Moberg Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enzymatica Publ with a short position of Moberg Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enzymatica Publ and Moberg Pharma.

Diversification Opportunities for Enzymatica Publ and Moberg Pharma

0.44

Correlation Coefficient

Enzymatica Publ  Moberg Pharma

Very weak diversification

The 3 months correlation between Enzymatica and Moberg is 0.44. Overlapping area represents the amount of risk that can be diversified away by holding Enzymatica publ AB and Moberg Pharma AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Moberg Pharma AB and Enzymatica Publ is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enzymatica publ AB are associated (or correlated) with Moberg Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Moberg Pharma AB has no effect on the direction of Enzymatica Publ i.e., Enzymatica Publ and Moberg Pharma go up and down completely randomly.

Pair Corralation between Enzymatica Publ and Moberg Pharma

Assuming the 90 days trading horizon Enzymatica publ AB is expected to under-perform the Moberg Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Enzymatica publ AB is 1.69 times less risky than Moberg Pharma. The stock trades about -0.02 of its potential returns per unit of risk. The Moberg Pharma AB is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  1,930  in Moberg Pharma AB on October 23, 2024 and sell it today you would lose (941.00) from holding Moberg Pharma AB or give up 48.76% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Enzymatica publ AB  vs.  Moberg Pharma AB

Enzymatica publ AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Enzymatica publ AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in February 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Moberg Pharma AB

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Moberg Pharma AB are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain fundamental drivers, Moberg Pharma may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Pair Trading with Enzymatica Publ and Moberg Pharma

The main advantage of trading using opposite Enzymatica Publ and Moberg Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enzymatica Publ position performs unexpectedly, Moberg Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Moberg Pharma will offset losses from the drop in Moberg Pharma's long position.

The idea behind Enzymatica publ AB and Moberg Pharma AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.